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The paper‘Oophorectomy and risk of Alzheimer's disease (AD) among hormone therapy users and 
non- users’ in this edition of JAD describes a very large (n=almost 40,000) Finnish Nation-wide AD 
Registered cohort and their age, sex and region-matched controls. In this cohort, oophorectomy for 
non-malignant indications decreased risk of Alzheimer’s disease (AD) by 11-15%. Hysterectomy 
alone decreased risk by 12% and oophorectomy with or without hysterectomy decreased risk by 14%. 
In a small group of women with bilateral oophorectomy and hysterectomy (n=92) risk was not 
increased. Risk of AD was independently increased with combined hormone use (HT, estrogen and 
progesterone) when this was used for less than 10 years. This paper is at odds with a number of other 
studies in this field, but adds another important piece to the puzzle on whether or not women who 
undergo surgical menopause should be treated with hormones up to the natural age of menopause to 
reduce dementia risk.  
Several retrospective observational studies suggested that surgical menopause may, when untreated, 
result in an increased risk for cognitive impairment/dementia risk in later life [1];	   [2]; [3]. These 
studies all found that the earlier the age at surgical menopause with hysterectomy without hormone 
treatment, the higher the risk of neurological functional decline. Data from the Mayo clinic with a 15 
to 52 year follow-up (average 25 years follow-up) reported that oophorectomy for non-malignant 
reasons (n=1472) increased the risk of cognitive impairment overall by 46% (CI=1.12-1.90) compared 
to referent women (n=1489). Oophorectomy before age 38 overall increased this risk by a factor 2.89 
(CI=1.86-4.48) [1]. Women undergoing unilateral oophorectomy were younger and separate analyses 
of this group showed an overall increased risk of CI by 64% (CI: 1.20-2.23). When unilateral 
oophorectomy occurred before age 34, the risk was 4.61 times higher (CI=2.52-8.43). Before age 41, 
this risk was almost a factor 2 higher (CI=1.26-3.11). This risk seemed dependent on hysterectomy 
being present, with overall the risk for cognitive impairment co-occurring with any oophorectomy 
increasing by 1.62 (CI=1.16-2.25), and by 1.83 (CI=1.07-3.11) for women with unilateral 
oophorectomy, while this association was only trend significant if the uterus was kept intact. 
‘Sparing’ was thus insufficient, as risk for dementia and Parkinson’s disease was increased after 
untreated unilateral oophorectomy with hysterectomy [4]; [1]. In a small Chinese study [5] 50 elderly 
women who had undergone unilateral oophorectomy with or without hysterectomy before age at 
natural menopause were compared to 50 demographically matched controls. Unilateral 
oophorectomy was associated with worse word recall, often one of the first markers of AD. In a large 
Danish study (Phung et al., 2010), women born before 1966 and alive on their 40th birthday without 
a dementia diagnosis prior to 1977 (n = 2,313,388) were followed from 1977, or the age of 40, until 
dementia diagnosis, death, or emigration in 2006. Overall, hysterectomy by itself did not increase the 
risk of dementia. When stratified by age at dementia diagnoses, hysterectomy was associated with an 
increased risk for early-onset dementia before the age of 50 which risk increased when accompanied 
by oophorectomy [hysterectomy alone (OR= 1.38, 95% confidence interval (CI) = 1.07–1.78), with 
unilateral oophorectomy (OR=2.10, 95% CI = 1.28–3.45), and with bilateral oophorectomy 
(OR=2.33, 95% CI = 1.44–3.77)]. 
However, according to one systematic review (1988 to 2007) this increased risk of dementia after 
surgical menopause was not always found. The review included a mix of RCT and observational 
studies without analyses of differences in design, methodology and participants included, and often 
not differentiating whether these women had been treated, whether hysterectomy had also been 
carried out and for the age at which the procedure had been done ([6], see also the included studies in 
this review: [7]; [8]; [9]; [10]). Differences in findings between studies could be further related to 
differences in data collection (self-report or medical records) and design (retro- or prospective data 
collection, the former being affected by recall). Recall of age at menopause or use of hormones is 
often impaired long before women develop other clear clinical symptoms of dementia, but this can act 
as a confound when retrospectively assessing risk factors for dementia [11]. In the present study in 
JAD, however, hormone use and AD was assessed through medical records.
A recent US based longitudinal study [3] by Bove et al (2013) included women without dementia at 
baseline (n=1884, mean age 78 years at assessment, n=607 had undergone surgical menopause). 
These participants were from 2 longitudinal studies of cognitive decline: the Religious Orders Study 
of older Catholic priests, nuns, and brothers that was started in 1994 and the Rush Memory and Aging 
Project that began enrolling residents of the Chicago area in 1997 who were followed for up to 18 
years. Each year of earlier surgical menopause was similar to the cognitive effects associated with 6 
months of aging. Age at time of surgical menopause, divided into quartiles (under 38, 38 to 43, 43 to 
49, and over 49 years) was also significant in reducing episodic memory (P = .0003) and semantic 
memory (P = .002) performance. These tests are both sensitive to early AD and were earlier found to 
be most responsive to estrogen treatment [12]. An earlier age at surgical menopause was also 
associated with a higher burden of the global measure of AD neuropathology (P = .038), in particular 
of neuritic plaques (P = .013). Measures were adjusted for age, education and smoking. In this study 
there was no association between age at natural menopause and cognition. Unfortunately, no data 
were available on type of surgery (with or without hysterectomy, unilateral etc).
Several smaller studies also showed that surgical menopause has an acute detrimental effect on 
cognitive (in particular verbal memory) function in a prospective study of Canadian women (with an 
average age of 45 years, n=50) assessed before and after oophorectomy and followed up for 7 months 
[13]. This was also seen in a cross-sectional study of 103 Italian women with an average age of 51 
years [14]. Again, the negative effect on verbal memory was worse when surgery was induced at a 
younger age [14]. In a prospective 6 month follow-up study of Egyptian women (average age 41 
years, n=53) undergoing surgical menopause resulted in a decline in global cognitive function, 
whereas controls had stable function over time [15]. However, treatment studies have shown that 
these effects are reversible.
Randomised controlled trials (RCT) in these early surgical menopausal women (mid to late forties on 
average) suggested that verbal memory and some other functions (abstract thinking, speed of 
information processing) showed reversed decline when using high dose intramuscular estradiol or 
testosterone compared to placebo [13]; [16];	  [12]. These findings were highly clinically relevant with 
one small study showing an average of 10 words more recalled with a high dose intramuscular 
injection of estradiol or testosterone [13]. Effects on verbal memory were smaller in another RCT 
from this group but remained stable with estradiol treatment, whereas the placebo group declined [17]
In the observational studies investigating risk for cognitive impairment/dementia, estrogen treatment 
up to age 50 [1]; or for 10 years within the 5 years around that natural age of menopause [3] 
eliminated the risk for cognitive impairment and dementia. In the study [3] by Bove et al (2014) of 
older women, there was no overall significant effect of HT on cognitive decline in this study with 
‘ever’ versus ‘never use’ or of ‘duration of use’. However, duration of HT in this study was associated 
with slower decline in global cognition when administered within a 5 year perimenopausal window. 
Again, this beneficial effect of hormone treatment in women who had undergone surgical menopause 
was not always found according to the earlier mentioned systematic review [6]. However, women in 
the RCTs described in that review [6] who did not respond to hormone treatment, were all older than 
50 years of age, and not finding effects of hormone treatment on cognition in that group are conform 
the later reviews by Rocca and colleagues. Similarly in the present study in JAD, hormone use was 
not found to modify the associations in this older cohort of postmenopausal women and if anything 
detrimental associations of combined hormone use with AD risk were found. 
The ‘Window of Opportunity theory or Critical Window theory’ substantiated by observational and 
basic sciences data suggests that effects of estrogens are most beneficial when given before or around 
the natural age at menopause, especially for women undergoing an earlier menopause [18]. 
Importantly, animal data providing convincing evidence for estradiol’s protective effect on brain 
function also included only ovariectomised animals who responded most significantly when treatment 
was initiated close to surgery, but not when this interval to treatment initiation was increased [19]. 
This theory, however, does not explain negative associations of hormone use with cognition. 
According to the ‘Healthy Cell Bias theory’ positive effects of estrogens are seen in healthy neuron 
cultures, but detrimental effects were found in older neurons already undergoing pathological change 
[20]. Conform this theory, two observational studies reported that surgical menopausal women who 
were still using hormone therapy a decade after menopause (around age 60 when they would be more 
at risk for neuronal pathological changes) actually had worse memory function than those untreated 
with hormones ([21] n=36, aged 51-72 years and [9] n=885, aged 60+). Similarly in the present study 
in JAD, use of hormones was associated with worse risk in this study of older women (average age 81 
years). Risk for AD was slightly decreased in women who had used hormones for more than 10 years 
which was a small group and may have been those who underwent surgery before the natural age of 
menopause. In contrast, one very small (n=35) cross-sectional study of women with bilateral 
oophorectomy (BSO) and hysterectomy aged over 65 years showed that those who were taking 
hormone treatment performed better on verbal and constructional abilty than non users [22] which 
would suggest against this theory. However, another much large (n=6110 (n=441 BSO), aged 45 to 64 
years) study [23]also showed that former, but not current hormone users who had undergone surgical 
menopause had better verbal fluency (a type of verbal memory test) at a 3 year follow-up than treated 
and untreated controls who had undergone natural menopause. 
Hence, the majority of these studies suggest that hormone treatment up to the age of 50 may be 
beneficial for neurological function in women who have undergone an early surgical menopause with 
hysterectomy and that this does not increase risk for dementia. On the other hand, continuing or 
initiating hormone treatment at an older age (>60 years of age) may confer risk for dementia and 
accelerate cognitive decline. These data call for a re-evaluation of estrogen treatment for women who 
become surgically menopausal before age 50. These data also reflect those of other health related 
interventions, where cessation of smoking, treating high blood pressure and high cholesterol may also 
be indicated in early middle age at the latest to reduce the risk of cognitive decline and dementia in 
later life [24].  It may be that hormone treatment in midlife for a particular subgroup of women (i.e. 
those who have undergone menopause before the natural average age at menopause) could be part of 
this, but only for a limited amount of time. 
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